SCHEMBL19789618

SCHEMBL19789618

COCC(=O)C1CCc2c(O)c3c(c(O)c2C1)C(=O)c1cccc(OC)c1C3=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.47
PIM1 P11309 1/20 0.47
ELANE P08246 8/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CTSG P08311 1/20 0.41
CTH P32929 1/20 0.39
S100A4 P26447 3/20 0.39
HSP90AA1 P07900 2/20 0.39
PAX8 Q06710 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
TCF4 P15884 1/20 0.38
CTNNB1 P35222 1/20 0.38
HIF1A Q16665 2/20 0.38
THRB P10828 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16848014 1.00 EGFR (0.47) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL22564644 0.91 EGFR (0.45) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL23022615 0.91 EGFR (0.48) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL13444092 0.91 EGFR (0.48) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL8171745 0.91 EGFR (0.48) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL23022613 0.89 ELANE (0.47) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL25823938 0.88 EGFR (0.46) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL23022621 0.88 EGFR (0.46) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL18909514 0.88 ELANE (0.42) EGFRPIM1ELANEMEN1KMT2A
SCHEMBL22873368 0.87 EGFR (0.51) EGFRPIM1ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020219748-A2 ANTI-CD117 ANTIBODIES AND USES THEREOF Magenta Therapeutics, Inc. (US) 2020-10-29 WO disclosed
WO-2020219770-A1 ANTI-CD117 ANTIBODIES AND USES THEREOF Magenta Therapeutics, Inc. (US) 2020-10-29 WO disclosed
WO-2020146432-A1 USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY Magenta Therapeutics, Inc. (US) 2020-07-16 WO disclosed
EP-2673004-B1 HYDROPHOBIC MODIFIED PEPTIDES AND THEIR USE FOR LIVER SPECIFIC TARGETING Ruprecht-Karls-Universität Heidelberg (DE) 2018-01-24 EP disclosed